<div id="readability-page-1">Valneva (NASDAQ:VALN) posted nine-month revenues that came in below market forecasts, though the vaccine developer reaffirmed its full-year guidance, sending its shares up 6% in Paris following the announcement. The company reported total nine-month revenue of €127 million and product sales of €119.4 million, missing the €132.3 million consensus estimate cited by Kepler Cheuvreux. Ixiaro, […]</div>

VALN

<p>Valneva 报告了九个月的收入为 1.27 亿欧元，低于市场预测的 1.323 亿欧元，但维持了全年指引。尽管未能达到收入预期，股价在巴黎上涨了 6%</p>

Valneva 收入未达预期但维持前景展望；股价上涨